Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
Heart Conduction System
Cardiac Complexes, Premature
Refractory Period, Electrophysiological
The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.
Sodium Channel Blockers
Cardiac Pacing, Artificial
Potassium Channel Blockers
Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis.
Torsades de Pointes
A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute, and QRS complexes with changing amplitude and twisting of the points. The term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long QT intervals exceeding 500 milliseconds or BRADYCARDIA. Torsades de pointes may be self-limited or may progress to VENTRICULAR FIBRILLATION.
Method in which prolonged electrocardiographic recordings are made on a portable tape recorder (Holter-type system) or solid-state device ("real-time" system), while the patient undergoes normal daily activities. It is useful in the diagnosis and management of intermittent cardiac arrhythmias and transient myocardial ischemia.
Electrophysiologic Techniques, Cardiac
Ventricular Premature Complexes
A type of cardiac arrhythmia with premature contractions of the HEART VENTRICLES. It is characterized by the premature QRS complex on ECG that is of abnormal shape and great duration (generally >129 msec). It is the most common form of all cardiac arrhythmias. Premature ventricular complexes have no clinical significance except in concurrence with heart diseases.
Ether-A-Go-Go Potassium Channels
A family of voltage-gated potassium channels that are characterized by long N-terminal and C-terminal intracellular tails. They are named from the Drosophila protein whose mutation causes abnormal leg shaking under ether anesthesia. Their activation kinetics are dependent on extracellular MAGNESIUM and PROTON concentration.
Atrial Premature Complexes
A type of cardiac arrhythmia with premature atrial contractions or beats caused by signals originating from ectopic atrial sites. The ectopic signals may or may not conduct to the HEART VENTRICLES. Atrial premature complexes are characterized by premature P waves on ECG which are different in configuration from the P waves generated by the normal pacemaker complex in the SINOATRIAL NODE.
Dose-Response Relationship, Drug
Tachycardia, Ectopic Atrial
Abnormally rapid heartbeats originating from one or more automatic foci (nonsinus pacemakers) in the HEART ATRIUM but away from the SINOATRIAL NODE. Unlike the reentry mechanism, automatic tachycardia speeds up and slows down gradually. The episode is characterized by a HEART RATE between 135 to less than 200 beats per minute and lasting 30 seconds or longer.
Potassium Channels, Voltage-Gated
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
Death, Sudden, Cardiac
Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
Calcium Channel Blockers
Long QT Syndrome
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).
Kv1.5 Potassium Channel
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Tachycardia, Ectopic Junctional
A rare form of supraventricular tachycardia caused by automatic, not reentrant, conduction initiated from sites at the atrioventricular junction, but not the ATRIOVENTRICULAR NODE. It usually occurs during myocardial infarction, after heart surgery, or in digitalis intoxication with a HEART RATE ranging from 140 to 250 beats per minute.
Myocardial Reperfusion Injury
Sodium Channel Agonists
Bundle of His
Small band of specialized CARDIAC MUSCLE fibers that originates in the ATRIOVENTRICULAR NODE and extends into the membranous part of the interventricular septum. The bundle of His, consisting of the left and the right bundle branches, conducts the electrical impulses to the HEART VENTRICLES in generation of MYOCARDIAL CONTRACTION.
An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.
The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.
Bicyclo Compounds, Heterocyclic
The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization).
Sperm Immobilizing Agents
A conical fibro-serous sac surrounding the HEART and the roots of the great vessels (AORTA; VENAE CAVAE; PULMONARY ARTERY). Pericardium consists of two sacs: the outer fibrous pericardium and the inner serous pericardium. The latter consists of an outer parietal layer facing the fibrous pericardium, and an inner visceral layer (epicardium) resting next to the heart, and a pericardial cavity between these two layers.
Voltage-Gated Sodium Channel Blockers
Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects.
Delayed Rectifier Potassium Channels
Connections between cells which allow passage of small molecules and electric current. Gap junctions were first described anatomically as regions of close apposition between cells with a narrow (1-2 nm) gap between cell membranes. The variety in the properties of gap junctions is reflected in the number of CONNEXINS, the family of proteins which form the junctions.
A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.
NAV1.5 Voltage-Gated Sodium Channel
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate.
Disease Models, Animal
Tachycardia, Atrioventricular Nodal Reentry
Abnormally rapid heartbeats caused by reentry of atrial impulse into the dual (fast and slow) pathways of ATRIOVENTRICULAR NODE. The common type involves a blocked atrial impulse in the slow pathway which reenters the fast pathway in a retrograde direction and simultaneously conducts to the atria and the ventricles leading to rapid HEART RATE of 150-250 beats per minute.
Cation Transport Proteins
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. NITROUS OXIDE is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical.
An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
Quaternary Ammonium Compounds
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Fatty Acids, Omega-3
A group of fatty acids, often of marine origin, which have the first unsaturated bond in the third position from the omega carbon. These fatty acids are believed to reduce serum triglycerides, prevent insulin resistance, improve lipid profile, prolong bleeding times, reduce platelet counts, and decrease platelet adhesiveness.
Calcium Channels, L-Type
Long-lasting voltage-gated CALCIUM CHANNELS found in both excitable and nonexcitable tissue. They are responsible for normal myocardial and vascular smooth muscle contractility. Five subunits (alpha-1, alpha-2, beta, gamma, and delta) make up the L-type channel. The alpha-1 subunit is the binding site for calcium-based antagonists. Dihydropyridine-based calcium antagonists are used as markers for these binding sites.
Body Surface Potential Mapping
Recording of regional electrophysiological information by analysis of surface potentials to give a complete picture of the effects of the currents from the heart on the body surface. It has been applied to the diagnosis of old inferior myocardial infarction, localization of the bypass pathway in Wolff-Parkinson-White syndrome, recognition of ventricular hypertrophy, estimation of the size of a myocardial infarct, and the effects of different interventions designed to reduce infarct size. The limiting factor at present is the complexity of the recording and analysis, which requires 100 or more electrodes, sophisticated instrumentation, and dedicated personnel. (Braunwald, Heart Disease, 4th ed)
Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing MYOCARDIAL REPERFUSION INJURY.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
This led to research for a new antiarrhythmic drug. As a result, procaine was discovered, which has similar cardiac effects as ... Procainamide works as an anti-arrhythmic agent and is used to treat cardiac arrhythmia. It induces rapid block of the ... Procainamide is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is classified by the ... This mechanism is responsible for the antiarrhythmic effect. However, due to the short duration of action, caused by rapid ...
Re-entry ventricular arrhythmia
Anti-Arrhythmic Drugs. Hurst's The Heart, Chapter 38. Mechanisms of Cardiac Arrhythmias and Conduction Disturbances. In V. ...
It is a class II antiarrhythmic. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic ... Jaillon P, Drici M (December 1989). "Recent antiarrhythmic drugs". The American Journal of Cardiology. 64 (20): 65J-69J. doi: ...
Bramah N. Singh
Singh, BN; Vaughan Williams, EM (August 1970). "A third class of anti-arrhythmic action. Effects on atrial and ventricular ... There, he worked on the anti-arrhythmic properties of drugs including amiodarone. Such work helped to refine the ... Nattel, S (26 November 1993). "Comparative mechanisms of action of antiarrhythmic drugs". The American Journal of Cardiology. ... Nattel, S (May 1991). "Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical ...
... is an antiarrhythmic medication of the class Ib type. This means it works by blocking sodium channels and thus ... "Lidocaine Hydrochloride (Antiarrhythmic)". The American Society of Health-System Pharmacists. Archived from the original on ... Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular ... Sheu SS, Lederer WJ (Oct 1985). "Lidocaine's negative inotropic and antiarrhythmic actions. Dependence on shortening of action ...
... (Tonocard) is a class Ib antiarrhythmic agent. It is no longer sold in the United States. Tocainide is a lidocaine ... October 1979). "New antiarrhythmic agents. 1. Primary alpha-amino anilides". Journal of Medicinal Chemistry. 22 (10): 1171-6. ... GB 1461602, "Primary Amino Acylanilides Methods of Making the Same and Use as Antiarrhythmic Drugs", issued 1974, assigned to ...
Benrixate, an antiarrhythmic agent. Ifenprodil & Ro-25-6981 (MI-4) TCS 46b ASS234 JTV-519 JX-401 KW 4099 [141364-05-8] 2- ...
Joshi GS, Burnett JC, Abraham DJ (2003). "Cardiac Drugs: Antianginal, Vasodilators, Antiarrhythmic". In Abraham DJ (ed.). ...
Richard N. Fogoros
Antiarrhythmic Drugs: A Practical Guide. 2 ed, 2007 Electrophysiologic Testing. 4 ed, 2006 Fixing American Healthcare: ...
Yoshidomi M, Sukamoto T, Morita T, Ito K, Nose T (1982). "Antiarrhythmic effect of KB-944, a new calcium antagonist. A ... It has antihypertensive and antiarrhythmic effects. Treatment of benzanilide with phosphorus pentasulfide or Lawesson's reagent ...
It is a class IV antiarrhythmic. Diltiazem was approved for medical use in the United States in 1982. It is available as a ...
D. George Wyse
... - antiarrhythmic drugs". Archived from the original on August 23, 2007. Retrieved 2008-08-27. CS1 maint: ... These trials include the Cardiac Arrhythmia Suppression Trial (CAST), the Antiarrhythmics Versus Implantable Defibrillators ( ... the reduction in use of certain antiarrhythmic agents. Wyse obtained his PhD in Pharmacology in 1969 from McGill University in ... "New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac ...
Heart rate variability
Thus, some antiarrhythmic drugs associated with increased mortality can reduce HRV. However, it is not known whether these ... Data exist for several antiarrhythmic drugs. Flecainide and propafenone but not amiodarone were reported to decrease time ...
Hattori Y, Hidaka T, Aisaka K, Satoh F, Ishihara T (April 1988). "Effect of SUN 1165, a new potent antiarrhythmic agent, on the ... Hattori Y, Inomata N (April 1992). "Modes of the Na channel blocking action of pilsicainide, a new antiarrhythmic agent, in ... Pilsicainide (INN) is an antiarrhythmic agent. It is marketed in Japan as サンリズム (Sunrythm). It was developed by Suntory ... Inomata N, Ishihara T, Akaike N (1987). "SUN 1165: a new antiarrhythmic Na current blocker in ventricular myocytes of guinea- ...
Its therapeutic range for an anticonvulsant effect is 10-20 μg/mL and for an antiarrhythmic effect 10-20 μg/mL. Avoid giving ... It is a class 1b antiarrhythmic. Digoxin toxicity: Intravenous formulation is drug of choice for arrhythmias caused by cardiac ... may be used in the treatment of ventricular tachycardia and sudden episodes of atrial tachycardia after other antiarrhythmic ...
Ferro G, Chiariello M, Tari MG, Vigorito C, Ungaro B, Condorelli M (May 1983). "Intropic effects of several antiarrhythmic ... Bunaftine (or bunaphtine) is an antiarrhythmic agent. It is classified in class III. Tamargo J (August 1980). " ...
"Chapter 5: Antiarrhythmic and Antianginal Agents". In Clarke FH (ed.). Annual Reports in Medicinal Chemistry. 12. Elsevier ...
Returning home he developed new models for the assessment of antiarrhythmic action, which were soon widely applied. He also ... The results and data on experimental cardiac arrhythmias and antiarrhythmic drugs were summarized with his co-authorship in the ... Walker.M.J.A. Antiarrhythmic Drug Research. Br, J, Pharmacol :2006, 147: S222-S231 Achievements of Professor Emeritus László ... He became interested in experimental cardiac arrhythmia and antiarrhythmic drugs, area rather unexplored at that time. Worked ...
... electrophysiologic and antiarrhythmic activity in humans". Journal of Cardiovascular Pharmacology. 15 (1): 144-9. doi:10.1097/ ...
... is an antiarrhythmic beta adrenergic antagonist. Koytchev, R; Alken, RG; Mayer, O; Smith, I; Greenwood, M (1996). " ... "Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone--a novel antiarrhythmic agent". ...
Essential fatty acid
Reiffel JA, McDonald A (August 2006). "Antiarrhythmic effects of omega-3 fatty acids". The American Journal of Cardiology. 98 ( ...
Lacerda AE, Kuryshev YA, Yan GX, Waldo AL, Brown AM (March 2010). "Vanoxerine: cellular mechanism of a new antiarrhythmic". ... that was in the midst of recruiting participants for a phase III human clinical trial for its use as a cardiac antiarrhythmic ...
It is not FDA approved for human use as an antiarrhythmic agent, and it is not included in the Vaughan Williams classification ... Sparteine is a class 1a antiarrhythmic agent; a sodium channel blocker. It is an alkaloid and can be extracted from scotch ... of antiarrhythmic drugs. It is also used as a chiral ligand in organic chemistry, especially in syntheses involving ...
As with all other antiarrhythmic agents, there is a risk of proarrhythmia associated with the use of flecainide. This risk is ... Flecainide is a class Ic antiarrhythmic agent. It works by decreasing the entry of sodium in heart cells, causing prolongation ... As with all class I antiarrhythmic agents, Flecainide increases the capture thresholds of pacemakers. Due to the narrow ... Morganroth J (1992). "Early and late proarrhythmia from antiarrhythmic drug therapy". Cardiovasc Drugs Ther. 6 (1): 11-14. doi: ...
Potassium channel blocker
... and Antiarrhythmic Actions", Antiarrhythmic Drugs: Mechanisms of Antiarrhythmic and Proarrhythmic Actions, Springer Berlin ... Ibutilide is the only antiarrhythmic agent currently approved by the Food and Drug Administration for acute conversion of ... Roukoz H; Saliba W (January 2007). "Dofetilide: a new class III antiarrhythmic agent". Expert Rev Cardiovasc Ther. 5 (1): 9-19 ... Potassium channel blockers used in the treatment of cardiac arrhythmia are classified as class III antiarrhythmic agents. Class ...
Several patents relate to the use of bispidine ligands for their antiarrhythmic and analgesic activity. It has been also found ... 5. Antiarrhythmic Activity of Selected , '-Disubstituted Bispidines". J. Med. Chem. 20 (12): 1668-1671. doi:10.1021/jm00222a026 ...
Torsades de pointes
It has also been shown as a side effect of certain anti-arrhythmic medications, such as sotalol, procainamide, quinidine, ... Lenz T. L.; Hilleman D. E. (July 2000). "Dofetilide, a New Class III Antiarrhythmic Agent". Pharmacotherapy. 20 (7): 776-86. ... of patients who receive QT-prolonging antiarrhythmic drugs. Most episodes will revert spontaneously to a normal sinus rhythm. ...
It is a class III antiarrhythmic drug. In the United States, the FDA approved label includes a claim for reducing ... Dronedarone is a non-iodinated class III anti-arrhythmic drug which helps patients return to normal sinus rhythm. This ... The drug also appears to exhibit activity in each of the 4 Vaughan-Williams antiarrhythmic classes. Dronedarone is less ... Dronedarone displays amiodarone-like class III antiarrhythmic activity in vitro and in clinical trials. ...
It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative ... Another concern about disopyramide has been the hypothetical potential for inducing sudden death from its type 1 anti-arrhythmic ... Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular ... Kim, S. Y.; Benowitz, N. L. (1990). "Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide ...
... is an antiarrhythmic medication used to treat and prevent a number of types of irregular heartbeats. This includes ... It is a class III antiarrhythmic medication. It works partly by increasing the time before a heart cell can contract again. ... with polymorphic ventricular tachycardia as it is associated with a prolonged QT interval which will be made worse with anti-arrhythmic ...
Antiarrhythmic agent - Wikipedia
The class I antiarrhythmic agents interfere with the sodium channel. Class I agents are grouped by what effect they have on the ... Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress ... Magnesium sulfate, an antiarrhythmic drug, but only against very specific arrhythmias which has been used for torsades de ... Common anti-arrhythmic drugs under the modernized classification according to Lei et al. 2018. Cardiac Arrhythmia Suppression ...
Novel Therapeutic Targets for Antiarrhythmic Drugs - Wikipedia
Novel Therapeutic Targets for Antiarrhythmic Drugs is a book edited by George Billman and published by John Wiley and Sons in ... Peter R. Kowey (2011). "Book Review: Novel Therapeutic Targets for Antiarrhythmic Drugs". Circulation. 123: e241-e242. doi: ... Mehanna agreed that Novel Therapeutic Targets for Antiarrhythmic Drugs did not adequately cover clinical aspects of drug ... "Description of Novel Therapeutic Targets for Antiarrhythmic Drugs". John Wiley and Sons. Retrieved December 11, 2014. CS1 maint ...
Antiarrhythmic Treatment in Atrial Fibrillation
Review the various types of antiarrhythmic agents used in the treatment of atrial fibrillation in this primer. How should the ... However, selection of antiarrhythmic drugs should be based on underlying heart disease and comorbidities, due to drug ... Table 2. Settings for Cautious Use of Antiarrhythmic Agents Drug Name. Settings for Exclusion or Cautious Use. ... Table 3. Selected Drug Interactions With Antiarrhythmic Agents Drug Name. Selected Drug Interactions. ...
Brugada Syndrome Medication: Antiarrhythmic Drugs
Pediatric Atrial Flutter Medication: Antiarrhythmic agents
Use of antiarrhythmic agents other than digoxin for the long-term suppression of atrial flutter in sinus node disease (a ... Antiarrhythmic agents. Class Summary. These agents alter the electrophysiologic mechanisms responsible for arrhythmia. ... This recommendation has gradually broadened to encompass other antiarrhythmic agents in patients with other types of repaired ... Sotalol is a class III antiarrhythmic agent that blocks potassium channels, prolongs action potential duration, and lengthens ...
Sodium channel selectivity filter regulates antiarrhythmic drug binding | PNAS
Local anesthetic antiarrhythmic drugs block Na+ channels and have important clinical uses. However, the molecular mechanism by ... Sodium channel selectivity filter regulates antiarrhythmic drug binding. Akihiko Sunami, Samuel C. Dudley Jr., and Harry A. ... Our findings show that the selectivity filter of Na+ channel is close to bound local anesthetic antiarrhythmic drug and that it ... Sodium channel selectivity filter regulates antiarrhythmic drug binding Message Subject (Your Name) has sent you a message from ...
Antiarrhythmic medication - definition of antiarrhythmic medication by The Free Dictionary
Noun 1. antiarrhythmic medication - a drug used to treat an abnormal heart rhythm antiarrhythmic, antiarrhythmic drug ... antiarrhythmic medication synonyms, antiarrhythmic medication pronunciation, antiarrhythmic medication translation, English ... antiarrhythmic medication. Also found in: Thesaurus.. Related to antiarrhythmic medication: Antiarrhythmic drugs, amiodarone, ... antiarrhythmic, antiarrhythmic drug. amiodarone, Cordarone - an antiarrhythmic drug (trade name Cordarone) that has potentially ...
Poisoning Due to Class 1B Antiarrhythmic Drugs | SpringerLink
Since most of the toxicity associated with class 1B antiarrhythmic drugs is dose-related, this review examines adverse effects ... Denaro, C.P., Benowitz, N.L. Poisoning Due to Class 1B Antiarrhythmic Drugs. Med Toxicol Adverse Drug Exp 4, 412-428 (1989). ... Since most of the toxicity associated with class 1B antiarrhythmic drugs is dose-related, this review examines adverse effects ... Antiarrhythmic efficacy, pharmacokinetics and clinical safety of tocainide in convalescent myocardial infarction patients. ...
What Animal Models are Useful in Selecting New Antiarrhythmic Drugs? | SpringerLink
... nor can any single animal model alone predict antiarrhythmic... ... many animal models are useful for evaluating new antiarrhythmic ... Left Anterior Descend Ventricular Fibrillation Antiarrhythmic Drug Antiarrhythmic Agent Ventricular Tachyarrhythmia These ... In: Clinical Pharmacology of Antiarrhythmic Therapy. Ed. Lucchesi, BR, Dingell, JV and Schwarz RP Jr. Raven Press, N.Y. pp. 31- ... Moore E.N., Spear J.F. (1985) What Animal Models are Useful in Selecting New Antiarrhythmic Drugs?. In: Morganroth J., Moore E. ...
antiarrhythmic medications - Symptoms, Treatments and Resources for antiarrhythmic medications
Antiarrhythmics Quiz - By daniellee703
Patent US20060212079 - Cardiac contractility modulation device having anti-arrhythmic capabilities ... - Google Patents
The anti-arrhythmic CCM device 30 includes an anti-arrhythmic therapy unit 38 and an a CCM unit 40. The anti-arrhythmic therapy ... The anti-arrhythmic therapy unit 68 may be any type of device or unit known in the art for delivering one or more anti- ... The anti-arrhythmic CCM device 30 also includes a power source 165 for providing power to the various components of the anti- ... an anti-arrhythmic module 50 is illustrated which is integrated within a CCM anti-arrhythmic device 51 (only a part of the ...
Antiarrhythmics | Heart and Stroke Foundation
Antiarrhythmics are a type of heart medication that prevent and treat abnormal heartbeats. Learn more about antiarrhythmics ... Antiarrhythmics slow down the electrical impulses in your heart so it can beat regularly again.. Antiarrhythmics can also help ... Antiarrhythmic drugs may be prescribed if your heart beats too quickly. Antiarrhythmics include several classes of drugs which ... What are antiarrhythmics?. Antiarrhythmic medications prevent and treat abnormal heartbeats (arrhythmias). Problems with your ...
The antiarrhythmic and anticonvulsant effects of dietary N-3 fatty acids. - PubMed - NCBI
The antiarrhythmic and anticonvulsant effects of dietary N-3 fatty acids.. Leaf A1, Kang JX, Xiao YF, Billman GE, Voskuyl RA. ... It has been shown in animals and probably in humans, that n-3 polyunsaturated fatty acids (PUFAs) are antiarrhythmic. We report ... appear at present to be the probable major antiarrhythmic mechanism of the PUFAs. ... recent studies on the antiarrhythmic actions of PUFAs. The PUFAs stabilize the electrical activity of isolated cardiac myocytes ...
Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate
... a new potent class I antiarrhythmic agent, was given to 152 patients (46 orally and 106 intravenously) over a period of 22 ... Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate Am Heart J. 1984 Feb;107(2):222-8. doi: 10.1016/0002- ... Flecainide acetate, a new potent class I antiarrhythmic agent, was given to 152 patients (46 orally and 106 intravenously) over ... Two patients who developed ventricular arrhythmias were taking other antiarrhythmic agents, and in this series proarrhythmic ...
PRIME PubMed | Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both?
... antiarrhythmic, proarrhythmic or both?. Download Prime PubMed App to iPhone, iPad, or Android ... von Schacky C. Omega-3 Fatty Acids: Antiarrhythmic, Proarrhythmic or Both. Curr Opin Clin Nutr Metab Care. 2008;11(2):94-9. ... "Omega-3 Fatty Acids: Antiarrhythmic, Proarrhythmic or Both?" Current Opinion in Clinical Nutrition and Metabolic Care, vol. 11 ... von Schacky C. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both? Curr Opin Clin Nutr Metab Care. 2008;11(2):94-9. ...
Alteration of defibrillation threshold by antiarrhythmic dru... : Critical Care Medicine
Propafenon, a new anti-arrhythmic drug (author's transl)
Antiarrhythmics, Inotropes, and Vasopressors: Medicine & Healthcare Book Chapter | IGI Global
Antiarrhythmics, Inotropes, and Vasopressors: 10.4018/978-1-4666-8603-8.ch010: Arrhythmias, low cardiac output syndromes, and ... Antiarrhythmic Agents. Antiarrhythmic drugs exert their action by blocking sodium, potassium or calcium. They are classified as ... "Antiarrhythmics, Inotropes, and Vasopressors." In Modern Concepts and Practices in Cardiothoracic Critical Care, ed. Adam S. ... "Antiarrhythmics, Inotropes, and Vasopressors." Modern Concepts and Practices in Cardiothoracic Critical Care. IGI Global, 2015 ...
Obesity Appears to Affect Response to Some Antiarrhythmic Medications
"This is the first time anyone has shown that there is a differential response to antiarrhythmic drugs for AFib," pointed out ... but how and why obesity affects response to antiarrhythmic drugs (AADs) remains unclear.. The report published in JAMA ... of AF compared with those without obesity who received sodium channel blocker antiarrhythmic drugs (6%). Both groups had ...
Free Pharmacology Flashcards about 34 ANTIARRHYTHMICS
Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics, Volume 2-3 - 1st Edition
Purchase Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics, Volume 2-3 - 1st Edition. ... Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics, Volume 2-3 1st Edition. ... Antiarrhythmic agents, which are pharmaceutical agents used to suppress fast rhythms of the heart (cardiac arrhythmias), ...
AntiarrhythmicsAntiarrhythmics are drugs that help control the heart rate and rhythm. They do this by either suppressing the ... Antiarrhythmics are drugs that help control the heart rate and rhythm. They do this by either suppressing the activity of ... Antiarrhythmics. Please note: reference image is displayed in place of Flash media. ... Antiarrhythmics include several classes of drugs such as sodium channel blockers, beta-blockers, potassium channel blockers, ...
Effects of Antiarrhythmic Agents on Cardiac Function
Studies the effects of antiarrhythmic agents on cardiac function. Membrane depressant agents; Cardiac effects of antiarrhythmic ... Determination of the drug levels following the administration of antiarrhythmic agent; Implications of antiarrhythmic agents ... PAPAVERINE AS AN ANTIARRHYTHMIC AGENT. Whipple, Gerald H. // Angiology;Nov1977, Vol. 28 Issue 11, p737 Suggests a chain of ... Examines the effectiveness of Norpace therapy among patients who had been on antiarrhythmic agents. Indications of toxicity in ...
Enhanced repolarization capacity: new potential antiarrhythmic strategy based on HERG channel activation
... Curr Med Chem. 2011;18 ... Suppression of IKr is the common mechanism of action of all class III antiarrhythmics, causing prolongation of the refractory ... Therefore, a new potential anti-arrhythmic strategy, based on augmentation of the repolarization reserve, has been emerged. ... Although the multiple ion channel activity of NS1643 may carry proarrhythmic risk, the rationale of antiarrhythmic strategy ...
Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties | Circulation
Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties. Charles Antzelevitch, ... Amiodarone is a potent antiarrhythmic agent used in the management of both atrial and ventricular arrhythmias. In addition to ... Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J ... The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report ...
Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation - Tabular View -...
Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation (MANTRA-PAF). The safety ... Medical antiarrhythmic treatment is only moderately effective and has the risk of severe side effects. The present study is a ... Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation. Official Title ICMJE ... Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective ...
Atrial Tachycardias Arising from Ablation of Atrial Fibrillation: A Proarrhythmic Bump or an Antiarrhythmic Turn?
In Silico Evaluation of the Potential Antiarrhythmic Effect of Epigallocatechin-3-Gallate on Cardiac Channelopathies
Antiarrhythmic Effect of E3G on SCN5A-Related Cardiac Syndrome, MEPPC, and EPVT. To investigate the potential antiarrhythmic ... including antiarrhythmics. Nevertheless, antiarrhythmic drugs are usually accompanied by some serious side effects. Thus, ... Antiarrhythmic Effect of E3G on the MEPPC and EPVT Syndromes. By implementing the experimental functional effects of E3G on the ... In order to evaluate the possible antiarrhythmic effect of E3G in the sitting of MEPPC and EPVT cardiac disorders, the ...
What is the role of class III antiarrhythmics in the treatment of atrial flutter?
Class III antiarrhythmic agents establish a chemical conversion to sinus rhythm. Intravenous amiodarone has been shown to slow ... encoded search term (What is the role of class III antiarrhythmics in the treatment of atrial flutter?) and What is the role of ... What is the role of class III antiarrhythmics in the treatment of atrial flutter?. Updated: Nov 09, 2018 ... class III antiarrhythmics in the treatment of atrial flutter? What to Read Next on Medscape. Related Conditions and Diseases. * ...
- Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. (wikipedia.org)
- Overall, he recommended the book, calling it "a worthwhile addition to the literature on cardiac arrhythmia and antiarrhythmic drugs. (wikipedia.org)
- Magnesium sulfate, an antiarrhythmic drug, but only against very specific arrhythmias which has been used for torsades de pointes. (wikipedia.org)
- In a review for ChemMedChem, medicinal chemistry professor Ahmed S. Mehanna agreed that Novel Therapeutic Targets for Antiarrhythmic Drugs did not adequately cover clinical aspects of drug development. (wikipedia.org)
- When you are on this pill avoid the intake of type 1A & 3 Antiarrhythmic such as Quinidine, Procainamide, Sotalol, Amiodarone, and alpha blockers. (safegenericpharmacy.com)
- Examples of affected drugs include antiarrhythmic drugs (such as propafenone, flecainide, quinidine) antipsychotics (such as thioridazine) tricyclic antidepressants (such as desipramine, imipramine) among others. (gayweddingsmag.com)
- Cordarone is an antiarrhythmic. (bhjournal.in)
- Domestic pigeons originally lived history the term manifest antiarrhythmic drugs to facilitate that has truly give. (okphotostudio.com)
- It has been reported to manifest antidepressant, anticonvulsant and antiarrhythmic acts as well as to possess antioxidant and lipid peroxidation activities. (totalayurvedacare.com)
- An antiarrhythmic Ia class drug, a blocker of the "fast" Na+ channels. (pharmasite.top)
- Antiarrhythmic (class IC). (drugfuture.com)
- Only for treatment of the following documented life-threatening recurrent ventricular arrhythmias that do not respond to other antiarrhythmics or when alternative agents are not tolerated: Recurrent ventricular fibrillation, recurrent hemodynamically unstable ventricular tachycardia. (nursingpath.in)